These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33348839)

  • 1. Plasma Inflammatory Biomarkers Associated with Advanced Liver Fibrosis in HIV-HCV-Coinfected Individuals.
    Chen X; Liu X; Duan S; Tang R; Zhou S; Ye R; Yang Y; Wang J; Yao S; He N
    Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33348839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.
    Mascia C; Lichtner M; Zuccalà P; Vita S; Tieghi T; Marocco R; Savinelli S; Rossi R; Iannetta M; Campagna M; Schiavone F; Mengoni F; Russo G; Mastroianni CM; Vullo V
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):644-655. PubMed ID: 28578937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study.
    Jiménez-Sousa MA; Berenguer J; Fernández-Rodríguez A; Medrano LM; Aldámiz-Echevarria T; Pérez-Latorre L; Díez C; Martín-Vicente M; Gutiérrez-Rivas M; Martínez I; Resino S
    Infect Genet Evol; 2019 Jan; 67():112-120. PubMed ID: 30336268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems.
    Fuster D; Tsui JI; Cheng DM; Quinn EK; Armah KA; Nunes D; Freiberg MS; Samet JH
    AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1110-6. PubMed ID: 23601055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.
    Charpentier C; Champenois K; Gervais A; Landman R; Joly V; Le Gac S; Larrouy L; Damond F; Brun-Vézinet F; Descamps D; Yazdanpanah Y
    PLoS One; 2013; 8(3):e59205. PubMed ID: 23527135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    Griesbeck M; Valantin MA; Lacombe K; Samri-Hassimi A; Bottero J; Blanc C; Sbihi Z; Zoorob R; Katlama C; Guiguet M; Altfeld M; Autran B;
    AIDS; 2017 Jun; 31(9):1223-1234. PubMed ID: 28492391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV Infection, HCV Coinfection, and Alcohol Use: Associations with Microbial Translocation and Immune Activation.
    Monnig MA; Cohen R; Ramratnam B; McAdams M; Tashima K; Monti PM
    Alcohol Clin Exp Res; 2019 Jun; 43(6):1126-1134. PubMed ID: 30908642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients.
    Medrano LM; Garcia-Broncano P; Berenguer J; González-García J; Jiménez-Sousa MÁ; Guardiola JM; Crespo M; Quereda C; Sanz J; Canorea I; Carrero A; Hontañón V; Muñoz-Fernández MÁ; Resino S;
    AIDS; 2018 Jun; 32(9):1095-1105. PubMed ID: 29438197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals.
    Rohrbach J; Stickel F; Schmid P; Thormann W; Kovari H; Scherrer A; Günthard HF; Vuichard D; Cavassini M; Ambrosioni J; Bernasconi E; Furrer H; Rauch A;
    Antivir Ther; 2014; 19(2):149-59. PubMed ID: 24036684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects.
    Li Y; Xie J; Han Y; Wang H; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Zhu T; Thio CL; Li T
    Medicine (Baltimore); 2016 Feb; 95(5):e2660. PubMed ID: 26844493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of Liver Fibrosis and Microbial Translocation to Immune Activation in Persons Infected With HIV and/or Hepatitis C Virus.
    Reid M; Ma Y; Scherzer R; Price JC; French AL; Huhn GD; Plankey MW; Peters M; Grunfeld C; Tien PC
    J Infect Dis; 2018 Mar; 217(8):1289-1297. PubMed ID: 29304196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.
    Lim JK; Tate JP; Fultz SL; Goulet JL; Conigliaro J; Bryant KJ; Gordon AJ; Gibert C; Rimland D; Goetz MB; Klein MB; Fiellin DA; Justice AC; Lo Re V
    Clin Infect Dis; 2014 May; 58(10):1449-58. PubMed ID: 24569533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial translocation is associated with advanced liver fibrosis among people with HIV.
    He J; Shi R; Duan S; Ye R; Yang Y; Wang J; Zu Z; Tang R; Gao J; Liu X; He N
    HIV Med; 2022 Oct; 23(9):947-958. PubMed ID: 35301782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical non-invasive assessment of liver fibrosis cannot replace biopsy in HIV-HCV coinfected patients.
    Kliemann DA; Wolff FH; Tovo CV; Alencastro PR; Ikeda ML; Brandão AB; Barcellos N; Fuchs SC
    Ann Hepatol; 2016; 15(1):27-32. PubMed ID: 26626637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.
    Keating SM; Dodge JL; Norris PJ; Heitman J; Gange SJ; French AL; Glesby MJ; Edlin BR; Latham PS; Villacres MC; Greenblatt RM; Peters MG;
    PLoS One; 2017; 12(9):e0181004. PubMed ID: 28902848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
    Nguyen Truong T; Laureillard D; Lacombe K; Duong Thi H; Pham Thi Hanh P; Truong Thi Xuan L; Chu Thi N; Luong Que A; Vu Hai V; Nagot N; Tuaillon E; Dominguez S; Lemoine M
    PLoS One; 2016; 11(5):e0153744. PubMed ID: 27148964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection.
    Hodowanec AC; Lee RD; Brady KE; Gao W; Kincaid S; Plants J; Bahk M; Mackman N; Landay AL; Huhn GD
    BMC Infect Dis; 2015 Apr; 15():190. PubMed ID: 25884329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus.
    French AL; Evans CT; Agniel DM; Cohen MH; Peters M; Landay AL; Desai SN
    J Infect Dis; 2013 Aug; 208(4):679-89. PubMed ID: 23687224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection.
    Lamoury FM; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J;
    BMC Infect Dis; 2016 Jun; 16():241. PubMed ID: 27246604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and predictors of liver disease in HIV-infected children and adolescents.
    Pokorska-Śpiewak M; Stańska-Perka A; Popielska J; Ołdakowska A; Coupland U; Zawadka K; Szczepańska-Putz M; Marczyńska M
    Sci Rep; 2017 Sep; 7(1):12309. PubMed ID: 28951598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.